CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS

Compound I, deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.

Saved in:
Bibliographic Details
Main Authors SILINA, Alina, ZHOU, Jinglan, KRENITSKY, Paul, HADIDA RUAH, Sara Sabina, MCCARTNEY, Jason, MILLER, Mark Thomas, UY, Johnny, MELILLO, Vito, ISHIHARA, Yoshihiro
Format Patent
LanguageEnglish
Lithuanian
Published 27.12.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Compound I, deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.
Bibliography:Application Number: LT2020US026331T